Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413089 | PMC |
| http://dx.doi.org/10.1007/s00277-008-0444-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].
Zhonghua Xue Ye Xue Za Zhi
October 2024
Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments.
View Article and Find Full Text PDFChange in hair texture with the use of pomalidomide for multiple myeloma: From straight to curly phenotype.
J Oncol Pharm Pract
November 2024
Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
Introduction: Pomalidomide is used for treating multiple myeloma in patients who have relapsed after prior treatment with lenalidomide and a proteasome inhibitor. Common side effects include mild cytopenias, and deep vein thrombosis. While papulo-erythematous rash has been described, hair effects are rare with this class of agents.
View Article and Find Full Text PDFImmunoglobulin D-Lambda Multiple Myeloma Initially Presenting in the Sphenoid Sinus, Orbital Apex, and Skull Base: A Systematic Review with a Case Report.
J Neurol Surg Rep
July 2024
Department of Otolaryngology-Head and Neck Surgery, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Article Synopsis
- Multiple myeloma (MM) initially manifesting in the sphenoid sinus and skull base is rare, with a systematic review of 34 cases highlighting the challenges of early diagnosis and treatment, particularly for the IgD-λ subtype.
- A unique case of IgD-λ MM showed symptoms like dizziness and blindness, leading to a confirmed diagnosis and a wide range of diagnostic tests, including advanced imaging and biopsies.
- The study emphasizes the importance of using CT and MRI scans for detecting bone damage, and suggests that endoscopic procedures are effective for tissue biopsies, which can improve diagnosis in asymptomatic regions like the paranasal sinuses.
Lambda light chain - restricted non - crystalline proximal tubulopathy with cast nephropathy in multiple myeloma: a case report and literature review.
BMC Nephrol
September 2024
Departments of Pathology, Xijing Hospital, School of Basic Medicine, Fourth Military Medical University, 169 Changle Western Street, Xi'an, 710032, Shaanxi, China.
Background: Multiple myeloma (MM) often causes renal tubular damage, such as the light chain cast nephropathy (LCCN) and the light chain proximal tubulopathy (LCPT). The excessive light chains deposited in the proximal and distal tubules usually manifest with different characteristics, leading to a rare coexistence of the two pathological conditions. Here we report a unique case of a patient with multiple myeloma (MM) who presented with acute kidney injury (AKI) due to dual conditions of λ light chain-restricted non-crystalline LCPT and LCCN.
View Article and Find Full Text PDFImmunoglobulin class-switch recombination: Mechanism, regulation, and related diseases.
MedComm (2020)
August 2024
Department of Pathogen Biology School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology Wuhan Hubei China.
Maturation of the secondary antibody repertoire requires class-switch recombination (CSR), which switches IgM to other immunoglobulins (Igs), and somatic hypermutation, which promotes the production of high-affinity antibodies. Following immune response or infection within the body, activation of T cell-dependent and T cell-independent antigens triggers the activation of activation-induced cytidine deaminase, initiating the CSR process. CSR has the capacity to modify the functional properties of antibodies, thereby contributing to the adaptive immune response in the organism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!